Trial Profile

A Study to Investigate the Tolerability of Subcutaneous Injections of LY3074828 Compared to Placebo

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LY900021 (Primary) ; Mirikizumab (Primary)
Indications Crohn's disease; Plaque psoriasis; Ulcerative colitis
Focus Adverse reactions
Sponsors Eli Lilly and Company (India) Pvt. Ltd

Most Recent Events

18 Jul 2019 Status changed from active, no longer recruiting to completed.
02 May 2019 Status changed from recruiting to active, no longer recruiting.
02 Mar 2019 Planned End Date changed from 28 May 2019 to 21 Jun 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com